Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
International Journal of Antimicrobial Agents|January 13, 2009
Global resistance trends and the potential impact on empirical therapyRaul IsturizHuman Vaccines & Immunotherapeutics|June 16, 2015
Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adultsRaul Isturiz, Chris WebberDrugs|June 22, 2002
Narrow versus broad spectrum antibacterials: factors in the selection of pneumococcal resistance to beta-lactamsClaude Carbon, Raul IsturizHuman Vaccines & Immunotherapeutics|February 20, 2019
Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: a review of available evidenceJustine Alderfer, Amit Srivastava, Raul Isturiz, et al.Expert Review of Vaccines|February 19, 2021
The rationale for use of clinically defined outcomes in assessing the impact of pneumococcal conjugate vaccines against pneumoniaBradford D Gessner, Raul Isturiz, Vincenza Snow, et al.Expert Review of Vaccines|August 8, 2017
Streptococcus pneumoniae serotype 19A: worldwide epidemiologyRaul Isturiz, Heather L Sings, Betsy Hilton, et al.Human Vaccines & Immunotherapeutics|June 13, 2020
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidenceErica Chilson, Daniel A Scott, Beate Schmoele-Thoma, et al.Antimicrobial Agents and Chemotherapy|May 23, 2003
Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studiesEthan Rubinstein, Raul Isturiz, Harold C Standiford, et al.JAMA Network Open|March 18, 2022
Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate VaccineAmber Hsiao, John Hansen, Julius Timbol, et al.Vaccine|November 19, 2018
Incidence of outcomes relevant to vaccine safety monitoring in a US commercially-insured populationDaina Esposito, Lina Titievsky, Daniel C Beachler, et al.Pageof 2